Delusion

Cognition Therapeutics is Recruiting for Lewy Body Dementia Phase 2 SHIMMER Trial in Seventeen Research Sites Across the U.S.

Retrieved on: 
Wednesday, October 12, 2022
Lewy body, Therapy, Diagnosis, Degenerative disease, Delusion, Vance DeGeneres, Lewy, Hallucination, Private Securities Litigation Reform Act, Retina, Patient, Sleep, MPH, Mental health, NIA, Dementia, Nasdaq, Awareness, Risk, LBD, University, Neurology, Lewy Body Dementia Association, Neuron, U.S. Securities and Exchange Commission, National, Â, Securities & Exchange Commission of Pakistan, SHIMMER, Safety, Cognition, DLB, GLOBE, Neurodegeneration, Brain, Intellectual property, Practitioner, Pathology, Central nervous system, Biomarker, Pharmaceutical industry, Medicine, MD

The Phase 2 SHIMMER study ( NCT05225415 ) is actively recruiting participants for these sites across the United States, including those that are Lewy Body Dementia Association centers of excellence added Anthony O. Caggiano, M.D., Ph.D., Cognitions chief medical officer and head of R&D.

Key Points: 
  • The Phase 2 SHIMMER study ( NCT05225415 ) is actively recruiting participants for these sites across the United States, including those that are Lewy Body Dementia Association centers of excellence added Anthony O. Caggiano, M.D., Ph.D., Cognitions chief medical officer and head of R&D.
  • This month is Lewy Body Dementia Awareness month with approximately over 1.4 million people in the United States suffering from the neurodegenerative disease, making it the second most common form of dementia.
  • Often misdiagnosed it also masks itself as Parkinsons disease and is the largest dementia most have never heard of.
  • This October, during Lewy Body Dementia Awareness Month, lets recommit to educating ourselves about LBD.

Karuna Therapeutics to Present Data from the Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia at the 35th European College of Neuropsychopharmacology (ECNP) Congress

Retrieved on: 
Thursday, October 6, 2022
Science, Neurology, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Clinical Trials, Quality of life, Congress, Drug Quality and Security Act, Medicine, Hospital, ECNP, Therapy, Life, Karuna, Delusion, Hallucination, European College of Neuropsychopharmacology, Annual report, NASDAQ, Patient, Government budget balance, Detail, Securities Act of 1933, Coronavirus, Psychosis, Knowledge, Goal, KRTX, Health, Adult, Securities Exchange Act of 1934, Safety, Clinical trial, Brain, Forward-looking statement, Life expectancy, Lists of diseases, COVID-19, Psychiatry, Central nervous system, Pharmaceutical industry, Schizophrenia

A poster presentation and symposium will include previously reported efficacy and safety data, as well as new additional safety data from the trial.

Key Points: 
  • A poster presentation and symposium will include previously reported efficacy and safety data, as well as new additional safety data from the trial.
  • Comprised of muscarinic agonist xanomeline and muscarinic antagonist trospium, it is designed to preferentially stimulate muscarinic receptors in the central nervous system.
  • Karuna Therapeutics is a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions.
  • Views and opinions expressed in this release are those of Karuna Therapeutics and do not necessarily reflect opinions of ECNP.

Acadia Pharmaceuticals Recognizes Rett Syndrome Awareness Month and Launches New Awareness Campaign, Rett Revealed

Retrieved on: 
Tuesday, October 4, 2022
Research, Mental Health, Women, Neurology, Genetics, Biotechnology, Pharmaceutical, Consumer, Health, Science, People, Consensus, CNS, MECP2, Incidence, Female, Drug development, Arc, Acadia Pharmaceuticals, Schizophrenia, LinkedIn, Form 10-K, Research, Symptoms of COVID-19, Nature, Prevalence, Industry, Risk, Penn State Milton S. Hershey Medical Center, Private Securities Litigation Reform Act, Twitter, Gait abnormality, Hallucination, Neurological disorder, FDA, Delusion, Medication, Neurology, U.S. Securities and Exchange Commission, Sex swing, National Institute of Neurological Disorders and Stroke, Science, Commission on Industrial Relations, Stroke, Security (finance), Patient, X chromosome, Lists of diseases, Central nervous system, National, Creativity, Annual report, Organization, Rett syndrome, JL, Awareness, Pharmaceutical industry, Diagnosis, Rett

Acadia Pharmaceuticals today announced the launch of Rett Revealed, a new awareness campaign that will highlight the lives of Rett patients through a photo mosaic designed by Emily Shifflet, a 27-year-old eye-gaze artist living with Rett syndrome.

Key Points: 
  • Acadia Pharmaceuticals today announced the launch of Rett Revealed, a new awareness campaign that will highlight the lives of Rett patients through a photo mosaic designed by Emily Shifflet, a 27-year-old eye-gaze artist living with Rett syndrome.
  • Rett Revealed is a wonderful opportunity for other Rett families to share their childs special moments and increase awareness that despite this devastating condition, there are unique and strong people living fully with Rett syndrome.
  • Acadia will recognize Rett syndrome awareness month by lighting its corporate headquarters purple.
  • Acadia will also connect with and lend support to Rett families at 15 locally organized events across the country, organized by the International Rett Syndrome Foundation and the Rett Syndrome Research Trust.

CJE SeniorLife and Elderwerks Partner with VR Vision to Develop Dementia Care Training Program Using Virtual Reality Technology

Retrieved on: 
Thursday, September 8, 2022
Immersion, Workforce, CJE SeniorLife, CEO, Technology, CJE, Caregiver, Program, View, Innovation, Solution, Learning, Curriculum, Quality of life, Education, Organization, Multimedia, Empathy, Housing, CEUS, ROI, Dementia, Adult, Samata (NGO), Delusion, Virtual reality, Knowledge, Engagement, Fortune 1000, Transport, Hoarding, Health, Efficiency, Residential care, Management, XR

TORONTO, Sept. 8, 2022 /PRNewswire/ - Chicago-based nonprofits CJE SeniorLife and Elderwerks Educational Services have partnered with Toronto-based virtual reality company VR Vision to launch Dementia Reality, the first virtual reality dementia program that combines skills training with real-life obstacles in a virtual environment.

Key Points: 
  • TORONTO, Sept. 8, 2022 /PRNewswire/ - Chicago-based nonprofits CJE SeniorLife and Elderwerks Educational Services have partnered with Toronto-based virtual reality company VR Vision to launch Dementia Reality, the first virtual reality dementia program that combines skills training with real-life obstacles in a virtual environment.
  • The new virtual educational model utilizes technology powered by VR Vision to immerse professional caregivers and better prepare them to help clients living with dementia.
  • Dementia Reality utilizes the latest in 360 video technology, delivered in virtual reality to create impeccably realistic, interactive content.
  • For training and upskilling employees at scale, VR Vision is pleased to partner with Fortune 1000 companies to raise training performance through immersive learning experiences.

Jerry Wonda produced LUNAClipse drops music video for “Minds on Fire” and Walks VMA Red Carpet

Retrieved on: 
Thursday, September 1, 2022
Lists of diseases, Assault, Twin Towers Correctional Facility, Twin Towers, Music, Culture, Darkness, Spirituality, Catharsis, LUNA, Mobb Deep, Textbook, Apocalypse, Thought, New, Human, GLOBE, Fugees, Delusion, World War II, Industry, Tourism, Vevo, Spotify

Out of that darkness has emerged a new champion for the nameless, faceless, forgotten masses, LUNAclipse.

Key Points: 
  • Out of that darkness has emerged a new champion for the nameless, faceless, forgotten masses, LUNAclipse.
  • This track also sparked the first of many collaborations with 16 Grammy-nominated Haitian producer Jerry Wonda and his Wonda Music label(The Fugees, Mary J.Blidge, Beyonce, Santana, John Legend).
  • The third installment in this music and video series, "Minds on Fire" is currently available for streaming on Vevo and Spotify.
  • LUNAclipse made his first in person appearance walking The MTV Music Awards Red Carpet with his producer Jerry Wonda .

Acadia Pharmaceuticals to Present at Upcoming Investor Conferences

Retrieved on: 
Thursday, September 1, 2022
Science, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Clinical Trials, Other Health, Schizophrenia, Twitter, Fireside chats, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Hallucination, Symptoms of COVID-19, Delusion, ACAD, Neurological disorder, Rett syndrome, Nasdaq, LinkedIn, Pharmaceutical industry

Acadia is advancing breakthroughs in neuroscience to elevate life.

Key Points: 
  • Acadia is advancing breakthroughs in neuroscience to elevate life.
  • For more than 25 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most.
  • We developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinsons disease psychosis.
  • Our clinical-stage development efforts are focused on treating the negative symptoms of schizophrenia, Rett syndrome and neuropsychiatric symptoms in central nervous system disorders.

Segal Trials Participation in Study Shows Positive Results From Phase 3 EMERGENT-2 KarXT in Schizophrenia

Retrieved on: 
Tuesday, August 23, 2022
Research, Mental Health, FDA, Clinical Trials, Biotechnology, Managed Care, Pharmaceutical, Health, Science, Other Science, NDA, Psychiatry, Safety, Caregiver, Hospital, Movement disorders, Therapy, Life expectancy, Brain, Infection, New Drug Application, Principal investigator, Insomnia, Quality of life, Neurology, PSG, Karuna, Weight gain, FDA, Trial, Interview, Adult, Hallucination, Delusion, Knowledge, Clinical trial, Health, Life, Government budget balance, Patient, Pharmaceutical industry, Schizophrenia, MD

Segal Trials, a privately held network of clinical research sites throughout South Florida has concluded a phase 3 EMERGENT-2 trial with Karuna Therapeutics.

Key Points: 
  • Segal Trials, a privately held network of clinical research sites throughout South Florida has concluded a phase 3 EMERGENT-2 trial with Karuna Therapeutics.
  • The study focused on evaluating the efficacy, safety, and tolerability of its lead investigational therapy, KarXT (xanomeline-trospium), in adults with schizophrenia.
  • The study was overseen by Segal Trials, Chief Scientific Officer, & Principal Investigator, Rishi Kakar, MD.
  • Segal Trials , founded in 1998, is a privately held network of research sites throughout South Florida conducting Phase I-IV research trials that have led to 56 FDA-approved medications and devices.

Acadia Pharmaceuticals Reports Second Quarter 2022 Financial Results

Retrieved on: 
Monday, August 8, 2022
Mental Health, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, FDA, Hallucination, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, U.S. Securities and Exchange Commission, Chronic pain, NDA, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Lists of diseases, Neuron, Annual general meeting, Private Securities Litigation Reform Act, Growth, Brain, Microglia, Schizophrenia, Society, Security (finance), Research, Dopamine, Patient, Therapy, Neurological disorder, Twitter, RPD, Form 10-K, Central nervous system, ACAD, Astrocyte, Safety, Drug development, PIN, Nature, Symptoms of COVID-19, GAAP, Â, Histamine, Delusion, ASCP, Pimavanserin, Nasdaq, Rett syndrome, LinkedIn, Advertising, Annual report, Food, Disease, Pharmaceutical industry, Medical device, Animal, Cryptocurrency, Tutoring

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the second quarter ended June 30, 2022.

Key Points: 
  • Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the second quarter ended June 30, 2022.
  • In the second quarter of 2022, NUPLAZID net sales increased 17% year-over-year, said Steve Davis, Chief Executive Officer.
  • For the six months ended June 30, 2022 and 2021, Acadia reported net product sales of $250.0 million and $221.8 million, respectively.
  • For the six months ended June 30, 2022 and 2021, research and development expenses were $204.5 million and $113.9 million.

Treatment Challenges in Alzheimer's Disease Psychosis Persist, Neurologists' Paper Explains

Retrieved on: 
Wednesday, August 3, 2022
Well, Diagnosis, Delusion, Psychosis, Dementia, Long-term care, Hallucination, CNSA, Patient, Education, Aggression, Multimedia, Health, Safety, FDA, Animal, Neurology, Face, MD, Caregiver, Agitation, Residential care, Pharmaceutical industry, Alzheimer's disease

TALLAHASSEE, Fla., Aug. 3, 2022 /PRNewswire/ -- Citing a "substantial unmet need," a new paper from the Clinical Neurological Society of America offers unique insights from health care providers into the delusions, aggression and agitation that often accompany Alzheimer's disease. Psychosis impacts roughly 2.2 million of the 5.5 million Americans living with Alzheimer's, devastating caregivers and frustrating health care providers, who have no FDA-approved medications to treat the symptoms.

Key Points: 
  • Whether it's visions of animals and people who aren't there, or an inability to recognize a spouse or even oneself in a mirror, symptoms of Alzheimer's disease psychosis are unsettling and often stigmatized.
  • Well-meaning family members sometimes struggle to care for their loved one in the face of aggression and mistrust, which can intensify over time, the paper explains.
  • Greater coordination and a better understanding of Alzheimer's disease psychosis are needed to provide optimal care in these scenarios, the paper notes.
  • Effective, FDA-approved treatments for Alzheimer's psychosis would offer significant value, the paper explains.

Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia (CIAS)

Retrieved on: 
Thursday, July 28, 2022
Food and Drug Administration, Cognitive deficit, ERP, Ageing, CNS, Safety, Disorder, Broad Institute, MELAS, CIAS, Company, LinkedIn, Șaeș, Quantitative electroencephalography, Population, Government budget balance, CYCN, Delusion, Alzheimer's disease, Neuropsychiatry, NO, Research, Biomarker, Nitric oxide, Stanley Center for Psychiatric Research at Broad Institute, ADV, AES, Guanylate cyclase, SGC, Cognition, GLOBE, Pharmacology, EEG, CGMP, Twitter, Food, Nasdaq, Mitochondrial encephalomyopathy, Therapy, Plasma, Trial of the century, Hallucination, Psychiatry, Movement, EDT, Inflammation, Drug development, Patient, Pharmacokinetics, Physiology, Dietary supplement, Pharmaceutical industry, Medical device, Online shopping, Schizophrenia

CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced positive topline data from its clinical study of CY6463 for the treatment of Cognitive Impairment Associated with Schizophrenia (CIAS) in individuals with stable schizophrenia on a stable, single, atypical antipsychotic regimen. Data from the 14-day, double-blind, randomized, placebo-controlled, multiple-ascending-dose study demonstrate that once-daily CY6463 was safe and well tolerated, with no reports of serious adverse events (SAEs), severe adverse events (AEs), or treatment discontinuation due to AEs. Study data demonstrate a strong effect on cognitive performance after two weeks of 15mg once-daily dosing. A broad positive movement on inflammatory biomarkers was also observed. These signals on exploratory endpoints provide further evidence of the pro-cognitive and anti-inflammatory effects of CY6463 observed in preclinical studies and prior clinical trials.

Key Points: 
  • I am encouraged by the promising cognition signals observed after only two weeks of CY6463 dosing in patients with stable schizophrenia.
  • These data demonstrate the therapeutic potential of amplifying sGC signaling in the CNS, including positive effects on cognition and inflammation, and support further development of CY6463 in diseases characterized by cognitive impairment.
  • The clinical study enrolled 48 participants with stable schizophrenia with no more than moderate positive symptoms and on a stable, single, atypical antipsychotic regimen.
  • Cognitive impairment is a core, debilitating, and untreated symptom of schizophrenia, with nearly all patients suffering from some cognitive deficits.